NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2025
0mins
Source: Globenewswire
Clinical Trial Results: NewAmsterdam Pharma presented late-breaking data from the BROADWAY and TANDEM Phase 3 trials, showing that obicetrapib significantly reduces LDL-C levels by up to 70% when used with statins and demonstrates a 21% reduction in major adverse cardiovascular events.
Potential Impact on Cardiovascular Disease: The findings suggest obicetrapib could be a crucial addition to current treatments for patients at risk of cardiovascular disease, addressing the unmet need for effective LDL-lowering therapies as many patients struggle to reach their cholesterol goals despite existing medications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
